Risperidone (Risperdal): Increased rate of cerebrovascular events in dementia trials

CMAJ. Canadian Medical Association Journal

Volumn 167, Issue 11, 2002, Pages 1269-1270

  Wooltorton, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE RECEPTOR; HALOPERIDOL; HISTAMINE RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR;

AGGRESSION; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DEMENTIA; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LIPID BLOOD LEVEL; MEDICAL DECISION MAKING; NEGATIVE SYNDROME; OBESITY; RECEPTOR BLOCKING; RISK ASSESSMENT; RISK MANAGEMENT; SHORT SURVEY; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0036436448     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (11)

1. Canadian Study of Health and Aging Working Group. Canadian Study of Health and Aging: Study methods of prevalence of dementia. CMAJ 1994;150:899-913.
2. Beers MH. Behavior disorders in dementia. In: The Merck Manual of Geriatrics. Whitehouse Station (NJ): Merck & Co. Inc.; 2000. p. 371-7.
3. Ballard C, O'Brien J. Treating behavioural disease and psychological signs in Alzheimer's disease. BMJ 1999;319:138-9.
4. Gauthier S. Advances in the pharmacotherapy of Alzheimer's disease. CMAJ 2002;166(5):616-23.
5. Tune LE. Risperidone for the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry 2001;62(Suppl 21):29-32.
6. Risperdal (risperidone) and Cerebrovascular Adverse Events in Placebo-controlled Dementia Trials [Dear Healthcare Professional Letter]. Toronto: Janssen-Ortho Inc.; 2002 Oct 11. Available: www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/industry/ risperdal1_e.pdf (accessed 2002 Oct 25).
7. Edwards JG. Risperidone for schizophrenia. BMJ 1994;308:1311-2.
8. Risperidol (risperidone) [product monograph]. In: Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacists Association; 2002. p. 1486-90.
9. Mintzer JE. Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. J Clin Psychiatry 2001;62(Suppl 21):23-5.
10. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: Weight gain, diabetes mellitus and lipid abnormalities. Can J Psychiatry 2001;46(3):273-81.
11. Grunfeld E, Glossop R, McDowell I, Danbrook C. Caring for elderly people at home: The consequences to caregivers. CMAJ 1997;157(8):1101-5.